New drugs in prostate cancer
نویسندگان
چکیده
منابع مشابه
New drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other...
متن کاملChemotherapy and New Drugs in Prostate Cancer
Prostate cancer (PrC) is the fourth most common cancer (for both sexes combined) and the second most common cancer in men (accounting for 15% of all new male cancer cases), with a worldwide incidence of approximately 1,111,200, a 5-year prevalence of 3,924,000, and a mortality incidence of 307,000 for the year 2012.1 Since the 1990s, the increasing use of prostate-specific antigen (PSA) testing...
متن کاملNew prostate cancer drugs: extending and improving life.
With the advent of new, life-prolonging therapies in advanced prostate cancer, the eff ects of therapy on the disease's most common complications—skeletal-related events and bone pain—and their eff ect in turn on health-related quality of life should be considered in addition to survival outcomes. AFFIRM 1 was a randomized phase 3 study of enzalutamide (an androgen receptor inhibitor) versus pl...
متن کاملDeveloping New Small Molecular Drugs for Prostate Cancer Therapy
Most of the early prostate cancer has no obvious symptoms, but its malignancy metastasis will cause largely deaths. The treatment options for patients with prostate cancer include traditional surgery, external beam therapy, hormone therapy, small molecular drug and cryosurgery. It was considered non-traditional treatments also can be used in alternative medicines for prostate cancer therapy. Th...
متن کاملPSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prostate International
سال: 2016
ISSN: 2287-8882
DOI: 10.1016/j.prnil.2016.05.001